American scientists are raising a red warning flag over proposed studies of the drug minocycline for several neurodegenerative conditions. Reporting in Lancet Neurology, the researchers say that patients taking the off-patent minocycline for Lou Gehrig's disease declined more rapidly than the control group taking a placebo. That report comes as Canada's MS Society is funding a Phase III trial to determine if the drug can work to slow MS if it is administered during the early stage of the disease.
- check out the report from the Canadian Press